Oncolytic Virotherapy Market Outlook:
Oncolytic Virotherapy Market size was valued at USD 20.36 billion in 2025 and is projected to reach USD 111.76 billion by the end of 2035, rising at a CAGR of 18.89% during the forecast period, from, 2026-2035. In 2026, the industry size of oncolytic virotherapy is assessed at USD 25.03 billion.
Currently, the market is experiencing unprecedented progress due to advances in genetic engineering, regulatory momentum. Newer viral constructs are being designed with immune-enhancing transgenes. There is a growing trend in combining oncolytic viruses and other cancer therapies, as we move toward a more unified approach to cancer treatment. In terms of regulatory approvals, Fast Track or Breakthrough Designation approval has the potential to expedite trials and move them forward more rapidly toward market approval. Furthermore, Japan's conditional approval of the HSV-based Teserapure for malignant glioma signifies that innovative oncolytic therapies are gaining traction on a global scale.
In terms of geography, North America remains firm in its place as the innovation capital—supported by large biotech financing, regulatory encouragement, and innovative clinical trial activity. Moreover, the Asia-Pacific region is growing rapidly with regulatory changes supporting increased clinical activity. Market growth in North America and the Asia Pacific is also supported by the emergence of personalized virotherapies that improve the precision and safety of treatment. In addition, collaborative efforts between biotechs, academic virologists, and AI-generated design platforms are helping to improve vector specificity and accelerate the breadth of pipelines. Collectively, all these developments are moving oncolytic virotherapy from a niche experimental therapeutic to an exciting foundation of new multi-modal cancer treatments.
